News
DXR
9.65
-2.92%
-0.29
Weekly Report: what happened at DXR last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at DXR last week (0408-0412)?
Weekly Report · 04/15 10:01
Daxor’s Promising Growth and Innovation Outlook Merit a Buy Rating
TipRanks · 04/15 09:17
DAXOR CORP <DXR.O>: ASCENDIANT CAPITAL MARKETS RAISES TARGET PRICE TO $24.5 FROM $24
Reuters · 04/15 03:08
Weekly Report: what happened at DXR last week (0401-0405)?
Weekly Report · 04/08 10:04
Weekly Report: what happened at DXR last week (0325-0329)?
Weekly Report · 04/01 10:03
Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL) and Daxor (DXR)
Vigil Neuroscience Inc has an analyst consensus of Strong Buy, with a price target of $19.33. Daxor has a 548.7% upside from current levels. 2 analysts have reiterated a Buy rating on Vigil Neuroscience Inc. The company's shares closed at $2.79 yesterday.
TipRanks · 03/27 11:30
Daxor acquires Volumex and Megatope from existing supplier
Healthcare Daxor acquires Volumex and Megatope from existing supplier from privately-held Iso-Tex Diagnostics. The company also acquired the exclusive rights to Glofil, a drug that measures glomerular filtration rate (GFR) The company projects the acquisitions to be cash flow positive.
Seeking Alpha · 03/25 12:41
Daxor Corporation Acquires Volumex And Megatope From Its Existing Supplier Along With Glofil To Enhance Existing Suite Of Diagnostics; No Financial Terms Disclosed
Daxor Corporation projects the acquisitions to be cash flow positive and accretive to earnings immediately. Daxor has also acquired the exclusive rights to Glofil, a drug that measures glomerular filtration rate. The acquisitions are expected to improve margins and increase revenue streams for the company. The company is the leader in blood volume measurement technology.
Benzinga · 03/25 12:11
Weekly Report: what happened at DXR last week (0318-0322)?
Weekly Report · 03/25 10:05
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics
Daxor Corporation is the global leader in blood volume measurement technology. The company has entered into a definitive agreement to acquire rights to manufacture from Iso-Tex Diagnostics, Inc. Daxor has also acquired the exclusive rights to Glofil, a drug that measures glomerular filtration rate.
Barchart · 03/25 07:00
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024
Barchart · 03/22 07:00
Daxor Announces As Of December 31, 2023, Daxor's Net Assets Were $34,010,384 Or $7.08 Per Share, Revenue Increased 31.8% Year On Year For 2023 Versus 2022, Provides Corporate Update In Letter To Shareholders
Daxor Corporation, the global leader in blood volume measurement technology issued a corporate update in a letter to shareholders on March 15, 2023. CEO Michael Feldschuh says the company is focused on improving outcomes for patients. Daxor's net assets increased to $34,000,000 as of December 31, 2022.
Benzinga · 03/18 19:09
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
Strong Start to 2024 with Unaudited Revenue Climbing 229.1% in First Two Months of 2024 YoY. Daxor Corporation is the global leader in blood volume measurement technology. The company filed its Annual Report to Shareholders on March 18, 2024. The report reveals its portfolio holdings as of December 31, 2023.
Barchart · 03/18 13:18
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Daxor Corporation is the global leader in blood volume measurement technology. The company issued a corporate update in a Letter to Shareholders on March 15, 2023 from CEO & President, Michael Feldschuh. Daxor Corp. Is a member of the S&P 500 Index.
Barchart · 03/18 13:18
Weekly Report: what happened at DXR last week (0311-0315)?
Weekly Report · 03/18 10:03
Daxor Announces Sales To Three New Hospitals Furthering Expansion Of Its User Base
Daxor Corporation announces the expansion of blood volume analysis (BVA) in three new hospitals. New analyzer purchases and utilization of Daxor's ezBVA Lab service. The company is the global leader in blood volume measurement technology. New acquisitions fuel BVA sales growth and underscore its clinical relevance.
Benzinga · 03/11 12:10
Weekly Report: what happened at DXR last week (0304-0308)?
Weekly Report · 03/11 10:02
Weekly Report: what happened at DXR last week (0226-0301)?
Weekly Report · 03/04 10:04
Weekly Report: what happened at DXR last week (0219-0223)?
Weekly Report · 02/26 10:09
More
Webull provides a variety of real-time DXR stock news. You can receive the latest news about DAXOR CORP through multiple platforms. This information may help you make smarter investment decisions.
About DXR
Daxor Corporation is a blood volume measurement technology company, which is focused on blood volume testing innovation. The Company has developed and marketed the Blood Volume Analyzer (BVA-100), the diagnostic blood test cleared by the food and drug administration (FDA) to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. It is also focused on advancing healthcare by enabling optimal fluid management with blood volume analysis. It has several ongoing trials in the areas of heart failure treatment with support from the National Institutes of Health (NIH) and is under contract developing analyzers.